SERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

Core Insights - Sera Prognostics Inc. reported a revenue of $17,000 for Q2 2025, a decrease from $24,000 in Q2 2024, while total operating expenses remained flat at $9.3 million [4][6] - The company is focusing on commercial momentum following the completion of its pivotal PRIME study, which is expected to enhance engagement with managed Medicaid and other organizations [3][9] - The net loss for the quarter was $8.0 million, slightly improved from $8.3 million in the same period last year, with cash reserves of approximately $108.5 million expected to support operations through 2028 [6][15] Financial Performance - Revenue for Q2 2025 was $17,000, down from $24,000 in Q2 2024 [4] - Total operating expenses were $9.3 million, consistent with the previous year [4] - Research and development expenses decreased by approximately 24% to $3.3 million, attributed to lower clinical study costs [4] - Selling, general, and administrative expenses increased to $6.0 million from $4.9 million, reflecting investments in commercial activities [5] - The net loss for the quarter was $8.0 million, compared to $8.3 million a year ago [6] Strategic Initiatives - The company is engaging Medicaid plans in targeted states, particularly those with high premature birth rates, to capitalize on commercial opportunities [9] - Sera Prognostics plans to publish full results of the PRIME study this year, along with additional data on health economic benefits and expected cost savings [9] - Recent leadership appointments aim to strengthen the company's commercial capabilities and investor relations [9] Product Overview - The PreTRM® Test is a blood-based biomarker test that predicts the risk of spontaneous preterm birth, allowing for earlier interventions [12] - The test is designed to provide individualized risk assessments during weeks 18 to 20 of pregnancy, enabling personalized clinical decisions [12]